APIS Assay Technologies has announced the acquisition of Beogenomics, a specialized software developer with proficiency in Bioinformatics and Artificial Intelligence (BIOX).
Beogenomics has been developing both on-prem and secure cloud-based data analysis solutions - helping customers design, build and run custom tailored genomics & proteomics pipelines. The start-up with capability will be integrated into Manchester-based APIS, supporting the launch of a new BIOX Service Line as part of the company’s ongoing Biomarker Research and Development activities.
APIS develops new tests for the prediction, prevention, and diagnosis of disease from discovery to regulatory approval. The company’s business model is based on three pillars: biomarker diagnostics development, molecular diagnostic contract development, and applied bioinformatics.
Bioinformatics and Artificial Intelligence are key competencies adding value to APIS’ in-house
Beogenomics will be fully integrated into the APIS workflow.
"We are delighted to announce our acquisition of Beogenomics, which offers strong operational and cultural fits. We look forward to welcoming the talented team and working together to expand our BIOX capacity internally, and build out a new, discrete, and externally-facing service line," Dr. Joachim Schorr, CEO of APIS, said.
"With the addition of Beogenomics’ proven expertise in bioinformatics – APIS can more effectively capture the exciting opportunities presented in the bioinformatics space," said Ian Kavanagh, COO of APIS.